Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;103(5):e226-e229.
doi: 10.3324/haematol.2017.183400. Epub 2018 Feb 22.

Usefulness of initial plasma dabigatran concentration to predict rebound after reversal

Nicolas Gendron  1   2   3 , Juliette Gay  1   2 , Marine Lemoine  4 , Pascale Gaussem  1   2   3 , Agnès Lillo-Le-Louet  4 , David M Smadja  5   2   3
Affiliations

Usefulness of initial plasma dabigatran concentration to predict rebound after reversal

Nicolas Gendron et al. Haematologica. 2018 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Initial plasma dabigatran concentrations of patients with or without dabigatran concentration rebound after idarucizumab injection. Sixteen of the 33 patients in the Reported case Group had a specific measure of dabigatran plasma concentrations by diluted thrombin time before and after idarucizumab injection At baseline, patients with no rebound had a significant lower median of dabigatran plasma concentration (139 ng/ml; range: 108–176) than patients with rebound (495 ng/ml; range: 215–3337.3; P=0.0035; non-parametric Mann-Whitney tests.).
See this image and copyright information in PMC

References

    1. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014; 124(15):2450–2458. - PubMed
    1. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–520. - PubMed
    1. Gendron N, Feral-Pierssens AL, Jurcisin I, et al. Real-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding. Clin Case Rep. 2017;5(3):346–350. - PMC - PubMed
    1. Tripodi A. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment. J Thromb Haemost. 2017;15(9):1882–1883. - PubMed
    1. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - Full cohort analysis. N Engl J Med. 2017;377(5):431–441. - PubMed

Publication types